Table 1.
Breast cancer studies n (%)
| Author | Type of microsphere | Type of mets (patients) | Response criteria | Response | Median OS |
| (publish date and study type) | (average dosage or activity) | @ 1st assessment | |||
| Gordon et al[50] | Therasphere | Breast (75) | RECIST and PET | RECIST | 6.6 mo |
| (8/2014 Epub, RS) | (mean 1.52 Gbq) | @ 1.4 mo (median) | 24 (35.3) PR | ||
| 43 (63.2) SD | |||||
| 1 (1.5) PD | |||||
| 7 lost | |||||
| PET | |||||
| 3 (12) CR | |||||
| 18 (72) PR or SD | |||||
| 4 (16) PD | |||||
| 50 lost | |||||
| Seyal et al[48] | Unspecified | Breast (21) | RECIST 1.1 | 34 lesions | None |
| (8/2014, RS) | (no dosage info) | 34 lesions | @ unspecified | 6 (17.7) PR | |
| 27 (79.4) SD | |||||
| 1 (2.9) PD | |||||
| Saxena et al[47] | SIR-Spheres | Breast (40) | RECIST | 2 (5) CR | 13.6 mo |
| (12/2013, RS) | (mean 1.67 Gbq) | @ 1 mo | 10 (26) PR | ||
| 15 (39) SD | |||||
| 11 (29) PD | |||||
| 2 lost | |||||
| Cianni et al[33] | SIR-Spheres | Breast (77) | RECIST and PET | 29 (56) PR | 11.5 mo |
| (1/2013, RS) | (median 1.9 Gbq) | @ 1.8 mo | 18 (35) SD | ||
| 5 (10) PD | |||||
| 25 ineligible | |||||
| Jakobs et al[39] | SIR-Spheres | Breast (30) | RECIST | 14 (61) PR | 11.7 mo (all) |
| (5/2008, PC) | (mean 1.9 Gbq) | @ 4.2 mo (median) | 8 (35) SD | 23.6 mo (responders) | |
| 1 (4) PD | 5.7 mo (nonresponders) | ||||
| 7 lost | |||||
| Coldwell et al[35] | SIR-Spheres | Breast (44) | RECIST and PET | RECIST | Median OS not reached |
| (3/2007, RS) | (median 2.1 Gbq) | @ 2.8 mo | 17 (47) PR | ||
| 17 (47) SD | 86% 14-mo survival | ||||
| 2 PD (5) PD | |||||
| 8 lost | |||||
| PET scans | |||||
| 42 (95) response | |||||
| 2 (5) no response/progression | |||||
| Bangash et al[31] | Therasphere | Breast (27) | WHO and PET | WHO | Median OS not given. |
| (5/2007, PC) | (median 1.70 Gbq, mean 2.05 Gbq) | @ 3 mo | 9 (39.1) CR/PR | 6.8 mo (ECOG 0) | |
| 12 (52.1) SD | 2.6 mo (ECOG 1,2,3) | ||||
| 2 (8.8) PD 4 lost | 9.4 mo (< 25% tumor burden) | ||||
| PET 17 (63) response | 2.0 mo (> 25% tumor burden) | ||||
| 10 (37) no response | |||||
| Cianni et al[34] | SIR-Spheres | Breast (32, data extracted from larger study) | RECIST | 14 (44) CR/PR | None |
| (1/2010, RS) | (mean 1.64 Gbq) | @ 1.8 mo | 11 (34) SD | ||
| 7 (22) PD | |||||
| Reiner et al[46] | SIR-Spheres | Breast (1, data extracted from larger study) | RECIST 1.1 | 1 (100) CR/PR | None |
| (1/2014, PC) | (mean 1.5 Gbq) | @ 4 mo | |||
| Pöpperl et al[45] | SIR-Spheres | Breast (4, data extracted from larger study) | PET | 3 (100) Regression | None |
| (4/2005, PC) | (mean 2.27 Gbq) | @ 3 mo | 1 lost |
PC: Prospective cohort study; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival; OR: Overall response.